TransMedics: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 5, 2026, TransMedics (NASDAQ:TMDX) announced full-year 2026 revenue guidance of $764 million to $774 million. The company is advancing several clinical initiatives to expand the use of its medical devices across donor organs. Three things management said stand out for long-term investors. Third-quarter revenue reached $203 million, up 41% year over year, despite the typical summer lull in donor activity. Increasing customer adoption of organ preservation technology helped offset a 6% drop in overall U.S. donor organ availability during the quarter. Management is expanding enrollment in its ENHANCE heart and DENOVO lung clinical programs, which use warm perfusion and cold storage options to broaden patient eligibility. These initiatives aim to capture thousands of annual procedures that currently use no machine preservation technology. Continue reading